XAIR
Beyond Air, Inc. NASDAQ Listed Jun 12, 2018$0.50
Pre-mkt
$0.51
-1.85%
Mkt Cap $2.5M
52w Low $0.43
1.2% of range
52w High $5.84
50d MA $0.70
200d MA $1.56
P/E (TTM)
-0.0x
EV/EBITDA
-0.6x
P/B
0.1x
Debt/Equity
0.9x
ROE
-504.6%
P/FCF
-0.4x
RSI (14)
—
ATR (14)
—
Beta
0.53
50d MA
$0.70
200d MA
$1.56
Avg Volume
317.5K
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
900 Stewart Avenue · Garden City, NY 11530 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | AMC | -0.75 | -0.85 | -13.3% | 1.05 | +8.6% | +2.9% | +0.0% | +0.9% | -7.3% | +0.0% | — |
| Nov 10, 2025 | AMC | -0.54 | -1.25 | -131.5% | 1.74 | -13.8% | -16.1% | +0.7% | -2.7% | -3.5% | -2.9% | — |
| Aug 12, 2025 | AMC | -1.50 | -1.53 | -2.0% | 3.16 | -14.6% | -22.5% | -5.3% | +0.0% | +3.4% | -4.6% | — |
| Jun 17, 2025 | AMC | -2.80 | -1.80 | +35.7% | 5.70 | -28.8% | -28.9% | +14.6% | -18.3% | -1.8% | -6.2% | — |
| Feb 10, 2025 | AMC | -0.24 | -3.00 | -1150.0% | 8.75 | +5.1% | -6.4% | -9.8% | +0.5% | +4.7% | -6.7% | — |
| Nov 11, 2024 | AMC | -6.00 | -5.60 | +6.7% | 10.20 | -14.0% | -3.0% | -2.3% | +9.7% | -5.4% | +1.5% | — |
| Aug 6, 2024 | AMC | -5.80 | -5.40 | +6.9% | 10.09 | +13.6% | -17.3% | +0.7% | +0.5% | +2.0% | -11.7% | — |
| Jun 24, 2024 | AMC | -9.40 | -7.20 | +23.4% | 26.80 | -27.6% | -51.5% | -2.4% | -8.5% | -7.3% | +18.3% | — |
| Feb 12, 2024 | AMC | -12.20 | -10.00 | +18.0% | 43.00 | -12.1% | -17.7% | +4.5% | +10.8% | -5.4% | +2.6% | — |
| Nov 13, 2023 | AMC | -9.40 | -10.20 | -8.5% | 40.60 | -26.1% | -31.0% | +23.6% | -9.0% | -4.8% | +6.0% | — |
| Aug 10, 2023 | AMC | -9.20 | -9.00 | +2.2% | 72.60 | -3.6% | -0.3% | -1.4% | -8.7% | -8.0% | -11.5% | — |
| Jun 22, 2023 | AMC | -8.80 | -13.40 | -52.3% | 114.10 | -13.2% | -18.8% | -2.6% | +5.8% | -2.5% | -1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | D. Boral Capital | Maintains | Buy → Buy | — | $0.69 | $0.70 | +1.4% | +4.7% | -6.9% | +2.7% | +3.5% | -0.6% |
| Mar 18 | D. Boral Capital | Maintains | Buy → Buy | — | $0.81 | $0.81 | +1.1% | +0.2% | -3.3% | +1.1% | +2.4% | -7.4% |
| Mar 10 | D. Boral Capital | Maintains | Buy → Buy | — | $0.86 | $0.86 | -0.1% | -4.0% | -2.6% | +0.9% | +1.2% | +1.2% |
| Jan 21 | D. Boral Capital | Maintains | Buy → Buy | — | $1.95 | $1.91 | -2.1% | -6.7% | -2.7% | -8.5% | -9.9% | -7.5% |
| Nov 11 | D. Boral Capital | Maintains | Buy → Buy | — | $1.74 | $1.50 | -13.8% | -16.1% | +0.7% | -2.7% | -3.5% | -2.9% |
| Aug 21 | D. Boral Capital | Maintains | Buy → Buy | — | $2.14 | $2.20 | +2.8% | -3.7% | +9.2% | +1.3% | -1.3% | +1.3% |
| Aug 13 | D. Boral Capital | Maintains | Buy → Buy | — | $3.16 | $2.70 | -14.6% | -22.5% | -5.3% | +0.0% | +3.4% | -4.6% |
| Aug 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.09 | $11.46 | +13.6% | -17.3% | +0.7% | +0.5% | +2.0% | -11.7% |
| Jun 25 | BTIG | Downgrade | Buy → Neutral | — | $26.80 | $19.40 | -27.6% | -51.5% | -2.4% | -8.5% | -7.3% | +18.3% |
| Jun 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $26.80 | $19.40 | -27.6% | -51.5% | -2.4% | -8.5% | -7.3% | +18.3% |
| Apr 30 | Truist | Maintains | Buy → Buy | — | $21.40 | $21.60 | +0.9% | +0.9% | +4.6% | +8.0% | +6.6% | -3.8% |
| Nov 14 | Truist | Maintains | Buy → Buy | — | $40.60 | $30.00 | -26.1% | -31.0% | +23.6% | -9.0% | -4.8% | +6.0% |
| Jul 21 | Truist | Maintains | Buy → Buy | — | $81.60 | $81.80 | +0.2% | -3.7% | -6.1% | -5.4% | -1.1% | -6.4% |
| Jun 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $114.10 | $99.00 | -13.2% | -18.8% | -2.6% | +5.8% | -2.5% | -1.5% |
| Jun 29 | Truist | Maintains | Buy → Buy | — | $115.60 | $134.00 | +15.9% | +8.1% | +7.0% | +10.9% | +14.0% | +17.7% |
| Jun 29 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $115.60 | $134.00 | +15.9% | +8.1% | +7.0% | +10.9% | +14.0% | +17.7% |
| Nov 12 | Truist | Maintains | Buy → Buy | — | $220.00 | $208.40 | -5.3% | +21.8% | +9.9% | -0.1% | +3.6% | -6.5% |
| Apr 28 | Truist | Maintains | Buy → Buy | — | $109.40 | $111.80 | +2.2% | +11.2% | +1.0% | +0.0% | -6.0% | -6.4% |
| Oct 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $89.40 | $90.00 | +0.7% | -6.7% | +7.2% | -1.6% | +6.8% | -4.3% |
| Sep 25 | Roth Capital | Maintains | Buy → Buy | — | $115.00 | $120.00 | +4.3% | +4.3% | -16.7% | +0.2% | +1.0% | +2.4% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
XAIR faces potential delisting from Nasdaq but plans to appeal, creating uncertainty about the company's exchange listing status that could significantly impact stock liquidity and institutional investor access.
Apr 15
8-K
Unknown — 8-K Filing
The reverse split signals financial distress, and with delisting risk looming by April 2026, XAIR faces existential pressure that will likely cause continued stock deterioration unless fundamentals improve dramatically.
Apr 10
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A carefully negotiated executive departure with strict confidentiality provisions suggests potential internal conflict or performance issues, warranting investor scrutiny of management stability and upcoming leadership announcements.
Apr 1
8-K · 7.01
! Medium
Beyond Air, Inc. -- 8-K 7.01: Regulation FD Disclosure
Beyond Air issued a press release on February 13, 2026, disclosing material information to investors through SEC filing, though specific details of the announcement remain unavailable in this summary.
Feb 13
8-K
Beyond Air, Inc. -- 8-K Filing
Beyond Air stockholders approved auditor WithumSmith+Brown for fiscal 2026 and increased equity plan shares by 850,000, supporting future employee compensation while maintaining accounting oversight.
Feb 2
Data updated apr 27, 2026 10:22am
· Source: massive.com